Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

(2010) E. Hertlein et al.   BLOOD

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

(2010) Q. Liu et al.   CLINICAL CANCER RESEARCH

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

(2010) Lapo Alinari et al.   mAbs

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

(2009) F. T. Awan et al.   BLOOD

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

(2009) Peter Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

Immunotherapy in mantle cell lymphoma: Anti-CD20-based therapy and beyond

(2007) Yuhong Zhou et al.   AMERICAN JOURNAL OF HEMATOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD